Details
Category: Volume 07 Issue 03 March 2019
Hits: 1339

Title: Safety and Effective Management of Type-2 Diabetes Mellitus Patients by using Sitagliptin

Authors: Chandana.T, Allahuddin.Syed

 DOI: https://dx.doi.org/10.18535/jmscr/v7i3.06

Abstract

Objectives: To study the safety and efficacy of the newer oral hypoglycemic agent sitagliptin in management of type-2 diabetes mellitus patients

Methods: This concurrent observational study was carried out in general medicine department of Rajiv Gandhi Institute Of Medical Sciences for a period of 6 months in which type 2 diabetes mellitus patients were recruited based on inclusion and exclusion criteria and were followed to evaluate the efficacy and safety of sitagliptin. Data was analyzed by using graph pad prism-student T-test.

Results: In our study we have recruited 41 patients who met our study criteria of which we categorized based on age and laboratory data, the majority of patients in the age group between 56-65 years (n=14, 34.15%), the RBS was reduced to Comparatively values of RBS, FBS, PPBS, HbA1C were reduced in follow up than base line value. RBS was reduced from 195.5 mg/dl to 155.68 mg/dl. FBS was 167.43 mg/dl at the base line, and then decreased to 135.21 mg/dl after follow-up. Likewise PPBS and HbA1C at base line were 196.6 mg/dl and 6.78 % respectively. Both were decreased to 157 mg/dl and 6.04 % respectively.

Conclusion: Based on results we can conclude that sitagliptin use was not associated with any risks and is effective in management of Type 2 diabetics, treatment with sitagliptin provided clinically meaningful reductions in HbA1C, RBS, FBS, PPBS by using this study we know that gliptins are much more safe and effective in the treatment of type 2 diabetes mellitus.

Keywords: Diabetes mellitus; Sitagliptin; Insulin. 

References

  1. T. Dipiro, Pharmacotherapy, 7th edition, 2008, published by the Mc Graw Hill Companies. Pg no. 147, 1206.
  2. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes. Indian J Med Res .Mar 2007;125(3):217-230
  3. Madhav D, Ram R, Dakshinamurty KV. Diabetes mellitus in India current status Ind j pharprac. Dec 2010; 42(10):4069-4071.
  4. Ramachandran A, Snehalatha C, Kapur A, Vijay V, MohanV, Das AK. Diabetes Epidemiology Study Group in India (DESI). High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001; 44 : 1094-101.14
  5. Weir GC, Bonner-Weir S. Five stages of evolving [beta]-cell dysfunction during progression to diabetes.  2004;53(Suppl 3):S16–21.
  6. Defronzo RA. Banting Lecture.From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. 2009;58:773–95.
  7. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49).UK Prospective Diabetes Study (UKPDS) Group. 1999;281:2005–12.
  8. Bell DS. A Comparison of agents used to manage type 2 diabetes mellitus: Need for reappraisal of traditional approaches. Treat Endocrinol. 2004;3:67–76.
  9. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–72.
  10. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus.The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541–9.
  11. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Diabetes Study Group. Diabetes Care. 1998;21:87–92.
  12. Shah SK, Saikia M, Burman NN, Snehalatha A. Risk factors of type 2 diabetes in urban population in north eastern India. Int J Diabetes Dev Countries 1999; 19: 144-147
  13. Kashyap SR, Bhatt DL, Wolski K, Watanabe RM, Abdul-Ghani M, Abood B, et al., Moderate Obesity and Type 2 Diabetes: Analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. Feb 25 2013;[Medline].
  14. Colagiuri S, Borch-Johnsen K, Glümer C, et al. There really is an epidemic of type 2 diabetes. Diabetologia 2005; 48 (8): 1459-1463.
  15. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28 (9): 2130-2135.
  16. Alvin C. Power; Diabetes mellitus. Harrisons; Principal of Internal Medicine; 17th edition; volume 2; 2275-2304.
  17. Joseph T. Dipiro, Robert L. Tablet. Dipiro, Pharmacotherapy A Pathological Approach; Seventh edition; 1205-42.
  18. Drug profile of voglibose http://www.micromedexsolutions.com/ micromedex2/ librarian/Search Term= vildagliptin &User SearchTerm=voglibose & SearchFilter=filter None&navitem= searchGlobal#. Accessed on 16/11/2015, at 11.15 am.
  19. Manuj Sharma. Comparative study of efficacy and safety of sitagliptin versus glimepiride in patients of type-2 diabetes mellitus inadequately controlled with metformin alone, International Journal of Advances in Medicine, 2016 Aug;3(3):564-68.
  20. International Diabetes Federation. Diabetes And Cardiovascular Disease. 2016. idf.org/cvd. Accessed 27 Oct 2016.
  21. Jacques N. New NICE guidelines for type II diabetes treatment. clinical update: Br J Clinic Pharm. 2009;1:167-8
  22. American diabetes association. Approaches to glycemic treatment. Diabetes Care. 2016;39(1):52- 9.
  23. http://www.diabetes.org/diabetes-basics/diagnosis/?loc=db-slabnav
  24. Srivastava S, Saxena GN, Keshwani P, Gupta R. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Japi. 2012;60:27-30.
  25. Anjoom M, Dutta S, Beg MA, Varma A, Bawa S, Kant R. Comparative evaluation of combination of metformin and glimepiride with that of metformin and sitagliptin in type 2 diabetes mellitus with respect to glycemic targets. Int J Med Sci Public Health. 2015;4:476-80.
  26. Hayati F, Hazim A, Sasongko TH, Siew HG, Wan WMI, Daud J, et al. Efficacy and safety of sitagliptin as a third therapeutic agent in the treatment of type 2 diabetes mellitus. J Diab Res Clin Met. 2014;3:10.
  27. D Tripathi, Essentials of Medical Pharmacology I.P Publications, 7thedition, 651-53.

Corresponding Author

Allahuddin Syed, Pharm D

Address:  Door no:3/95, Sivalingam Pille street, Near NTR circle,  Kadapa-516001. A.P, India

Mobile No: 9177355779, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.